Elephantine Psoriasis. A case report
Main Article Content
Keywords
Skin Diseases, Psoriasis, Biological Therapy, Hyperkeratotic Psoriasis
Abstract
Abstract
Background: Hyperkeratotic psoriasis is a rare variant that includes forms such as elephantiasis, considered the rarest. It is characterized by thick, persistent plaques, resembling elephant skin, located mainly on the extremities and buttocks. Early detection and appropriate treatment, including systemic therapies, are essential for its management.
Clinical case: A 58-year-old male patient presented in 2018 with dermatosis on his forehead, right elbow, and the backs of both hands. He was initially diagnosed with seborrheic dermatitis and chronic lichen simplex and received multiple topical therapies without improvement. In 2024, he developed new, disseminated lesions on his elbows, hands, and both legs, characterized by hyperkeratotic plaques and excoriations. A biopsy confirmed the diagnosis of elephantiasis variant hyperkeratotic psoriasis. Treatment with ustekinumab was initiated, resulting in significant improvement of the lesions.
Conclusions: Elephantine psoriasis is a rare and difficult-to-treat variant, with few reported cases, which hinders the standardization of its management. Biologic therapies represent an effective alternative for improving prognosis, reducing complications, and preventing progression to other associated pathologies. Disseminating these cases is essential to expanding knowledge of this variant and optimizing available therapeutic options, for the benefit of patients.
References
1. Sugumaran D, Yong ACH, Stanslas J. Advances in psoriasis research: From pathogenesis to therapeutics. Life Sci. 2024;355:122991. doi: 10.1016/j.lfs.2024.122991.
2. Orzan OA, Tutunaru CV, Lanoși SL. Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders. Int J Mol Sci. 2025;26(2):749. doi: 10.3390/ijms26020749. PMID: 39859462; PMCID: PMC11766135.
3. Dand N, Mahil SK, Capon F, et al. Psoriasis and Genetics. Acta Derm Venereol. 2020;100(3):adv00030. doi: 10.2340/00015555-3384.
4. Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6.
5. Bilal J, Malik SU, Riaz IB, et al. Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician. Am J Med. 2018;131(10):1146-1154. doi: 10.1016/j.amjmed.2018.05.013.
6. Sadatmadani SF, Malakoutikhah Z, Mohaghegh F, et al. Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review. Curr Ther Res Clin Exp. 2022;96:100676. doi: 10.1016/j.curtheres.2022.100676.
7. Koley S, Mandal RK, Chatterjee K,et al. Elephantine Psoriasis with Papillomatosis and Alternating Hypogranulosis and Hypergranulosis. Indian J Dermatol. 2015;60(3):264-7. doi: 10.4103/0019-5154.156367.
8. Pan Y, Zou J, Hu T,et al. Psoriasis: A Multidimensional Review of Onset, Progression, Treatment, and the Evolution of Disease Models. Mol Diagn Ther. 2025;29(3):345-366. doi: 10.1007/s40291-025-00776-8.
9. Petit RG, Cano A, Ortiz A, et al. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci. 2021;22(9):4983. doi: 10.3390/ijms22094983.
10. Chakith MRS, Pradeep S, Gangadhar M, et al. Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches. PeerJ. 2025;13:e19325. doi: 10.7717/peerj.19325.
11. Kayaçetin S, Öcalan DT, Gül Ü. Comparison of Histopathological Findings in Psoriasis According to the Lesion Location From Biopsy. Am J Dermatopathol. 2024;46(6):353-357. doi: 10.1097/DAD.0000000000002648.
12. Tanghetti E, Stein-Gold L, Lain E, et al. Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis. J Drugs Dermatol. 2025;24(6):590-598. doi: 10.36849/JDD.8720.
13. Tafazzoli Z, Meibodi NT, Torabi S. Solitary ostraceous psoriasis treatment: A rare presentation of a common disease. Dermatol Ther. 2021;34(1):e14567. doi: 10.1111/dth.14567.
14. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci. 2023;24(17):13313. doi: 10.3390/ijms241713313.
15. Chat VS, Uppal SK, Kearns DG, et al. Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. Dermatol Ther. 2021;34(4):e14974. doi: 10.1111/dth.14974.
16. Gönülal M, Balcı DD, Öztürk A, et al. Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience. J Dermatolog Treat. 2023;34(1):2241941. doi: 10.1080/09546634.2023.2241941.
17. Londoño-García AM, Castro-Ayarza JR, Franco Franco MD, et al. Latin American consensus on psoriasis severity classification. An Bras Dermatol. 2025;100(3):539-547. doi: 10.1016/j.abd.2024.09.010.
18. González-Parra S, Daudén E. Psoriasis and Depression: The Role of Inflammation. Actas Dermosifiliogr (Engl Ed). 2019;110(1):12-19. doi: 10.1016/j.ad.2018.05.009.
19. Krstanović K, Kroflin K, Kroflin L, et al. Psoriasis and mental health: a psychodermatological approach with an emphasis on psychotherapy. Psychiatr Danub. 2024;36(1):7-16. doi: 10.24869/psyd.2024.7.
20. Hołdrowicz A, Żebrowska A. Molecular Link Between Psoriasis and Depression-Update on Pathophysiology. Int J Mol Sci. 2025;26(6):2467. doi: 10.3390/ijms26062467.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.